Insel Gruppe Ag, University Hospital Bern
Clinical trials sponsored by Insel Gruppe Ag, University Hospital Bern, explained in plain language.
-
Kidney nerve treatment studied for stubborn heart rhythm problem
Disease control TerminatedThis study looked at whether a procedure called renal denervation could help people with recurrent atrial fibrillation (an irregular heartbeat) that keeps coming back even after standard treatment. The procedure uses energy to calm certain nerves near the kidneys. Only 6 people t…
Phase: NA • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
Chewing gum for weight loss in kids? study ends early
Disease control TerminatedThis study tested whether a special chewing gum with fiber could help obese children lose weight and improve their metabolism. About 93 children were to take part, but the study was stopped early. The gum aimed to change gut and mouth bacteria to support weight control.
Phase: NA • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated Jun 11, 2026 12:08 UTC
-
Painkiller showdown: is extra paracetamol needed for cancer patients on opioids?
Symptom relief TerminatedThis study looked at whether cancer patients already taking strong opioids (like morphine) can stop taking regular paracetamol without their pain getting worse. It included 7 adults with stable pain. The trial was stopped early, so results are limited.
Phase: PHASE4 • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Symptom relief
Last updated Jun 22, 2026 12:06 UTC
-
Could a tailored Check-Up schedule improve life after head and neck cancer?
Knowledge-focused TerminatedThis study aimed to find the best way to follow up with patients after they finish curative treatment for head and neck cancer. Researchers compared a personalized follow-up schedule, tailored to each patient's needs, with the usual one-size-fits-all approach. The goal was to see…
Phase: NA • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated Jun 22, 2026 12:04 UTC
-
Blood test may predict dangerous MS rebound after stopping popular drug
Knowledge-focused TerminatedThis small, early-terminated study explored whether measuring certain receptors on immune cells could predict disease activity and rebound risk in multiple sclerosis patients taking or stopping ozanimod. Researchers analyzed blood samples from 23 adults with relapsing-remitting M…
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Knowledge-focused
Last updated Jun 22, 2026 11:57 UTC